Tracking Valuations, page-6

Great work, very informative....some interesting assumptions in there though, like :

If the Lower Back Pain and Advanced Heart Failure trials are both completed with Phase 3 and reading out in a couple months........ Why is Edison estimating 2023 for heart failure, and 2022 for lower back pain commercialization?

There seems to be a lot more interest in the heart failure benefits at the moment - possibly due to Covid 19 appearing to effect the heart / blood vessels and MSB cells appearing to benefit in this area?

Also interesting that ARDS is excluded from the valuation also.... One would assume this is a no brainer product extension if Covid -19 trial goes well, and we get excess product supply with reduction of Covid ARDS patients to treat ( If it happens ).

Exciting that is for sure.....

Could it be the next market Darling, and reach PE 40 +